New Rx for Schedule-II Stimulants for ADHD Increased During Pandemic
By Lori Solomon HealthDay Reporter
WEDNESDAY, Jan. 17, 2024 -- Incident use of common behavioral health medications remained relatively stable during the COVID-19 pandemic, with the exception of those for attention-deficit/hyperactivity disorder (ADHD), according to a study published online Jan. 10 in JAMA Psychiatry.
Grace Chai, Pharm.D., M.P.H., from the U.S. Food and Drug Administration in Silver Spring, Maryland, and colleagues assessed changes in incident prescriptions dispensed for five drug classes commonly used to treat depression, anxiety, ADHD, and opioid use disorder (OUD) before and during the COVID-19 pandemic. The analysis included data from IQVIA National Prescription Audit on incident prescriptions from April 2018 to March 2022.
The researchers found that incident prescriptions increased from roughly 51.5 million before the COVID-19 pandemic to about 54.0 million during the pandemic. Nurse practitioners showed the largest unadjusted percentage increase in incident prescriptions across all drug classes, ranging from 7 percent for benzodiazepines to 78 percent for buprenorphine medication for OUD. The largest increases by patient characteristics were for schedule-II stimulants and nonstimulant ADHD drugs among patients aged 20 to 39 years (30 and 81 percent, respectively) and female patients (25 and 59 percent, respectively). Incident prescriptions for antidepressants, benzodiazepines, and buprenorphine for OUD did not significantly change.
"Additional research is needed to differentiate increases due to unmet need versus overprescribing, highlighting the need for further ADHD guideline development to define treatment appropriateness," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Further Support and Information on COVID-19
Read this next
FDA Approves First Liquid, Nonstimulant ADHD Treatment, Onyda XR
MONDAY, June 3, 2024 -- The U.S. Food and Drug Administration has approved once-daily Onyda XR (clonidine hydrochloride) as the first liquid, nonstimulant treatment for...
No Decline in Cardiovascular Events Seen With COVID-19 Vaccine After Acute Coronary Syndromes
MONDAY, June 3, 2024 -- Patients who have received at least one COVID-19 vaccine dose after acute coronary syndromes do not have a reduced risk for cardiovascular events...
Pharmacological Treatment of ADHD May Cut Some Forms of Criminality
WEDNESDAY, May 29, 2024 -- Pharmacological treatment may reduce some types of criminality among adolescents and young adults with attention-deficit/hyperactivity disorder (ADHD)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.